Related Experiment Video

Updated: Jun 2, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Current status of methods to assess cancer drug resistance

Theodor H Lippert1, Hans-Jörg Ruoff, Manfred Volm

  • 1Medical Faculty, University of Tübingen, Tübingen, Germany. Theodor-Lippert@web.de

International Journal of Medical Sciences
|April 14, 2011
PubMed

Insights

Rapid assessment methods for chemotherapy drug resistance in malignant tumors are described. These tests, including cell culture and PET scans, enable early diagnosis to improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Drug resistance is a primary cause of chemotherapy failure in malignant tumors.
  • Resistance can be intrinsic (pre-existing) or acquired (drug-induced).
  • Current diagnosis methods for drug resistance are often delayed, occurring after significant treatment duration.

Purpose of the Study:

  • To describe methods for the rapid assessment of drug resistance in cancer.
  • To highlight the potential of early drug resistance diagnosis for improved patient outcomes.

Main Methods:

  • Review of literature on three main classes of drug resistance tests: fresh tumor cell culture, cancer biomarker tests, and positron emission tomography (PET) tests.
  • Evaluation of methods based on molecular processes, specifically the metabolic activities of cancer cells.

Main Results:

  • Fresh tumor cell culture tests allow in-vitro diagnosis before treatment.
  • PET tests enable in-vivo diagnosis after a short treatment period.
  • Cancer biomarker tests show potential but are largely in the development stage.

Conclusions:

  • Rapid drug resistance surveillance offers significant progress in cancer therapy management.
  • Early diagnosis avoids ineffective and potentially harmful drug therapies.
  • Individualized resistance testing facilitates personalized cancer treatment strategies.
Keywords:
cancer biomarker testscancer drug resistancein vitro cancer drug resistance testsin vivo cancer drug resistance tests

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...